Phase 3 Trial Shows Adding Imdelltra to First-Line Treatment Helps Patients With SCLC Live Longer
Amgen's phase 3 trial (DeLLphi-305) showed that adding Imdelltra (tarlatamab) to Imfinzi (durvalumab) as maintenance therapy improved overall and progression-free survival for extensive-stage small cell lung cancer (ES-SCLC) patients compared to Imfinzi alone. The trial enrolled 563 patients, and no new safety concerns were identified. Full results are pending. Imdelltra is not yet approved for this use.
How this was made
The 30-second read
Why it matters
The announcement provides fresh, material data that could influence Amgen's valuation and pipeline expectations.
Market read
New pivotal trial data for a large‑cap biotech may drive short‑term stock movement and inform longer‑term oncology market dynamics.
What to watch
Potential competition from other bispecific agents and the pending FDA review timeline could moderate the upside.
Background
Amgen's DeLLphi-305 trial is the first phase 3 study to show a bispecific T‑cell engager improves survival in first‑line maintenance for extensive‑stage small cell lung cancer.
Ticker impact
Amgen announced its phase 3 DeLLphi-305 trial met its primary endpoint, showing the Imdelltra plus Imfinzi regimen improves overall survival versus Imfinzi alone.
likely upward pressure as market prices in the survival benefit
The trial result is new, material, and from a large‑cap biotech; however, detailed survival numbers are still pending, so the magnitude of the move is uncertain.
Market effects
May lift other SCLC‑focused biotech stocks and reinforce confidence in bispecific T‑cell engager platforms.
US biotech sector could see modest gains; limited immediate impact on broader markets.
Relevant to global oncology investors, but primary effect is on US‑listed Amgen.
Counterpoint
Investors may wait for full survival data before committing, as early trial signals can be tempered by safety or efficacy nuances.
Key entities
- CompanyAmgen
Biopharma company reporting positive phase 3 trial results.
- DrugImdelltra (tarlatamab)
Bispecific T‑cell engager evaluated in the trial.
